[go: up one dir, main page]

WO1998031355A3 - Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease - Google Patents

Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease Download PDF

Info

Publication number
WO1998031355A3
WO1998031355A3 PCT/GB1998/000105 GB9800105W WO9831355A3 WO 1998031355 A3 WO1998031355 A3 WO 1998031355A3 GB 9800105 W GB9800105 W GB 9800105W WO 9831355 A3 WO9831355 A3 WO 9831355A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
methyl
propylnorapomorphine
cathecol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/000105
Other languages
French (fr)
Other versions
WO1998031355A2 (en
Inventor
Dereck Alan Woodcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Britannia Pharmaceuticals Ltd
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of WO1998031355A2 publication Critical patent/WO1998031355A2/en
Publication of WO1998031355A3 publication Critical patent/WO1998031355A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A medicament is disclosed for treating Parkinson's disease which is in the form of a pack comprising a dosage of N-propyl norapomorphine (NPA) physiologically acceptable salts or prodrugs thereof and a dosage of a catechol-O-methyl-transferase (COMT) inhibitor.
PCT/GB1998/000105 1997-01-16 1998-01-14 Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease Ceased WO1998031355A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9700855A GB2321190B (en) 1997-01-16 1997-01-16 Pharmaceutical composition
GB9700855.1 1997-01-16

Publications (2)

Publication Number Publication Date
WO1998031355A2 WO1998031355A2 (en) 1998-07-23
WO1998031355A3 true WO1998031355A3 (en) 1998-09-11

Family

ID=10806094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000105 Ceased WO1998031355A2 (en) 1997-01-16 1998-01-14 Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease

Country Status (2)

Country Link
GB (1) GB2321190B (en)
WO (1) WO1998031355A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (en) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
JP3947103B2 (en) * 2000-07-14 2007-07-18 エフ．ホフマン−ラ ロシュ アーゲー A method to detect a predisposition to hepatotoxicity
FI20012242A0 (en) * 2001-11-19 2001-11-19 Orion Corp New pharmaceutical compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (en) * 1976-12-13 1978-07-07 Sterling Drug Inc Propyl:nor:apomorphine di:ester(s) - used for treating Parkinsonism, have longer duration of action than the acetate
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (en) * 1995-05-26 1996-11-28 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717643A (en) * 1967-05-04 1973-02-20 Sterling Drug Inc N-substituted-norapomorphines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (en) * 1976-12-13 1978-07-07 Sterling Drug Inc Propyl:nor:apomorphine di:ester(s) - used for treating Parkinsonism, have longer duration of action than the acetate
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (en) * 1995-05-26 1996-11-28 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COUDORE ET AL: "Effect of Tolcapone on Plasma and Striatal Apomorphine Disposition in Rats", NEUROREPORT, vol. 8, no. 4, 3 March 1997 (1997-03-03), pages 877 - 880, XP002065840 *
KOPIN: "The Pharmacology of Parkinson's Disease Therapy: An Update", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 33, 1993, pages 467 - 495, XP002065844 *
KUNTZER ET AL: "Treatment of Parkinson's Disease", EUROPEAN EUROLOGY, vol. 36, no. 6, November 1996 (1996-11-01), pages 396 - 408, XP002065845 *
LIMOUSIN ET AL: "Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinson's Disease", CLINICAL NEUROPHARMACOLOGY, vol. 18, no. 3, 1995, pages 258 - 265, XP002065842 *
MCKENZIE AND WHITE: "Evidence for the Methyation of Apomorphine by Catechol-O-Methyl-Transferase in vivo and in vitro", BIOCHEMICAL PHARMACOLOGY, vol. 22, 1973, pages 2329 - 2336, XP002065841 *
TÖRNWALL AND MANNISTO: "Effects of Three Types of Catechol O-Methylation Inhibitors on L-3,4-Dihydroxyphenylalanine-Induced Circling Behavior in Rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 250, no. 1, 1993, pages 77 - 84, XP002065843 *

Also Published As

Publication number Publication date
GB2321190A (en) 1998-07-22
GB9700855D0 (en) 1997-03-05
GB2321190B (en) 2000-09-20
WO1998031355A2 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
NL301005I1 (en)
NZ504618A (en) Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
MXPA03003895A (en) Controlled release hydrocodone formulations.
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1258245A3 (en) Accelerated release composition containing bromocriptine
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2002000209A3 (en) Gabapentin analogues for sleep disorders
EP0866656A4 (en) Inhibition of tumor necrosis factor alpha
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
IL119417A (en) Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
EP0744176A3 (en) Methods for inhibiting bone loss
WO1998031355A3 (en) Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease
WO2001068076A3 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
EP0978287A4 (en) MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
HK1041475A1 (en) Process for manufacture of l-dopa ethyl ester
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
FI953725A0 (en) Use of ornithine aminotransferase inhibitors in the manufacture of a medicament for the treatment of Alzheimer's disease
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
HUP9900354A3 (en) Use of condensed 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions treating and preventing diseases related with the inhibition of lipide peroxidation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533930

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09582650

Country of ref document: US

122 Ep: pct application non-entry in european phase